This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Incyte Corp. shed 3.2% to $60.00 on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 1.1% to 5,614.66 and Dow Jones Industrial Average falling 0.6% to 41,581.31.
This was the stock's second consecutive day of losses.
Incyte Corp. closed 28.5% short of its 52-week high of $83.95, which the company reached on November 8th.
The stock demonstrated a mixed performance when compared to some of its competitors, as Alnylam Pharmaceuticals Inc. fell 3.5% to $244.30, Bio-Techne Corp. rose 0.4% to $62.83, and BioMarin Pharmaceutical Inc. remained unchanged.
Trading volume totaled 3.3 million, compared to the 50-day average of 1.7 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
March 18, 2025 16:35 ET (20:35 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。